Published in Eur Arch Psychiatry Clin Neurosci on November 01, 2009
Deep brain stimulation for psychiatric disorders. Dtsch Arztebl Int (2010) 2.60
Consensus on guidelines for stereotactic neurosurgery for psychiatric disorders. J Neurol Neurosurg Psychiatry (2014) 1.57
Ethical issues in deep brain stimulation. Front Integr Neurosci (2011) 1.01
Deep Brain Stimulation and the Search for Identity. Neuroethics (2011) 1.00
Ethics of the electrified mind: defining issues and perspectives on the principled use of brain stimulation in medical research and clinical care. Brain Topogr (2013) 0.97
Potential utility of optogenetics in the study of depression. Biol Psychiatry (2012) 0.91
Characterization of spontaneous Parkinsonism in drug-naive patients with nonaffective psychotic disorders. Eur Arch Psychiatry Clin Neurosci (2011) 0.85
Proceedings of the Second Annual Deep Brain Stimulation Think Tank: What's in the Pipeline. Int J Neurosci (2015) 0.82
Health, Happiness and Human Enhancement-Dealing with Unexpected Effects of Deep Brain Stimulation. Neuroethics (2011) 0.81
Deep brain stimulation in the treatment of depression. Dialogues Clin Neurosci (2014) 0.79
The ethics of neuromodulation for anorexia nervosa: a focus on rTMS. J Eat Disord (2014) 0.77
What was new, interesting and frequently cited in 2009? Eur Arch Psychiatry Clin Neurosci (2010) 0.75
Deep Brain Stimulation in Anorexia Nervosa: Hope for the Hopeless or Exploitation of the Vulnerable? The Oxford Neuroethics Gold Standard Framework. Front Psychiatry (2017) 0.75
Deep brain stimulation for treatment-resistant depression. Neuron (2005) 12.39
Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci (2007) 4.46
Mechanisms of deep brain stimulation. Mov Disord (2002) 3.91
Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology (2007) 3.81
Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med (2008) 3.52
Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or both. Clin Neurophysiol (2004) 3.22
Translational principles of deep brain stimulation. Nat Rev Neurosci (2007) 3.10
Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry (2008) 3.00
Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry (2008) 2.86
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord (2006) 2.72
Deep brain stimulation. Annu Rev Neurosci (2006) 2.65
Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology (2006) 2.59
Unilateral deep brain stimulation of the nucleus accumbens in patients with treatment-resistant obsessive-compulsive disorder: Outcomes after one year. Clin Neurol Neurosurg (2009) 2.57
Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry (2008) 2.55
Deep brain stimulation in 18 patients with severe Gilles de la Tourette syndrome refractory to treatment: the surgery and stimulation. J Neurol Neurosurg Psychiatry (2007) 2.03
Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. Lancet (1999) 1.79
Prospective randomized double-blind trial of bilateral thalamic deep brain stimulation in adults with Tourette syndrome. J Neurosurg (2007) 1.46
Stimulating personality: ethical criteria for deep brain stimulation in psychiatric patients and for enhancement purposes. Biotechnol J (2008) 1.44
Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of thalamus. Lancet (1999) 1.44
Deep brain stimulation of the nucleus accumbens shell attenuates cocaine priming-induced reinstatement of drug seeking in rats. J Neurosci (2008) 1.37
Deep brain stimulation of the nucleus accumbens and the internal capsule in therapeutically refractory Tourette-syndrome. J Neurol (2007) 1.33
Nucleus accumbens deep brain stimulation produces region-specific alterations in local field potential oscillations and evoked responses in vivo. J Neurosci (2009) 1.22
Deep brain stimulation for psychiatric disorders. Neurosurg Clin N Am (2003) 1.10
Deep brain stimulation of the nucleus accumbens reduces ethanol consumption in rats. Pharmacol Biochem Behav (2009) 1.00
Electrical stimulation of the anterior limbs of the internal capsules in patients with severe obsessive-compulsive disorder: anecdotal reports. Neurosurg Clin N Am (2003) 0.91
DBS therapy for the vegetative state and minimally conscious state. Acta Neurochir Suppl (2005) 0.78
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet (2008) 6.24
Empathy decline and its reasons: a systematic review of studies with medical students and residents. Acad Med (2011) 4.40
WPA guidance on how to combat stigmatization of psychiatry and psychiatrists. World Psychiatry (2010) 4.26
Genome-wide association study of alcohol dependence. Arch Gen Psychiatry (2009) 3.08
Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull (2008) 2.59
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry (2009) 1.71
Remission of alcohol dependency following deep brain stimulation of the nucleus accumbens: valuable therapeutic implications? J Neurol Neurosurg Psychiatry (2007) 1.56
Neuregulin 1 ICE-single nucleotide polymorphism in first episode schizophrenia correlates with cerebral activation in fronto-temporal areas. Eur Arch Psychiatry Clin Neurosci (2008) 1.55
Response and remission criteria in major depression--a validation of current practice. J Psychiatr Res (2010) 1.52
Remediation of impairments in facial affect recognition in schizophrenia: efficacy and specificity of a new training program. Schizophr Res (2005) 1.48
Catatonia in DSM-5. Schizophr Res (2013) 1.43
Prediction of psychosis by mismatch negativity. Biol Psychiatry (2010) 1.38
Genome-wide significant association between alcohol dependence and a variant in the ADH gene cluster. Addict Biol (2011) 1.37
Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci (2004) 1.34
Deep brain stimulation of the nucleus accumbens and the internal capsule in therapeutically refractory Tourette-syndrome. J Neurol (2007) 1.33
Twelve-month prevalence, comorbidity and correlates of mental disorders in Germany: the Mental Health Module of the German Health Interview and Examination Survey for Adults (DEGS1-MH). Int J Methods Psychiatr Res (2014) 1.32
Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biol Psychiatry (2008) 1.31
Definition and description of schizophrenia in the DSM-5. Schizophr Res (2013) 1.28
Attenuated psychosis syndrome in DSM-5. Schizophr Res (2013) 1.24
Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5. Schizophr Res (2013) 1.21
Neural correlates of working memory dysfunction in first-episode schizophrenia patients: an fMRI multi-center study. Schizophr Res (2006) 1.21
Structure of the psychotic disorders classification in DSM-5. Schizophr Res (2013) 1.16
Cognitive functions in a patient with Parkinson-dementia syndrome undergoing deep brain stimulation. Arch Neurol (2009) 1.15
Sensory gating revisited: relation between brain oscillations and auditory evoked potentials in schizophrenia. Schizophr Res (2007) 1.14
Side effects of atypical antipsychotics: a brief overview. World Psychiatry (2008) 1.13
Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord (2008) 1.13
Neuropsychological profiles in different at-risk states of psychosis: executive control impairment in the early--and additional memory dysfunction in the late--prodromal state. Schizophr Bull (2010) 1.10
Modern modularity and the road towards a modular psychiatry. Eur Arch Psychiatry Clin Neurosci (2008) 1.06
Stability of emotional dysfunctions? A long-term fMRI study in first-episode schizophrenia. J Psychiatr Res (2007) 1.06
Deconstructing Psychosis conference February 2006: the validity of schizophrenia and alternative approaches to the classification of psychosis. Schizophr Bull (2007) 1.05
Detection of changed regional cerebral blood flow in mild cognitive impairment and early Alzheimer's dementia by perfusion-weighted magnetic resonance imaging. Neuroimage (2007) 1.04
Differential brain activation during facial emotion discrimination in first-episode schizophrenia. J Psychiatr Res (2008) 1.03
German research network on schizophrenia-bridging the gap between research and care. Eur Arch Psychiatry Clin Neurosci (2003) 1.01
Predictors of relapse in the year after hospital discharge among patients with schizophrenia. Psychiatr Serv (2012) 1.00
Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Interv Psychiatry (2007) 1.00
Deep Brain Stimulation and the Search for Identity. Neuroethics (2011) 1.00
Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia. Eur Neuropsychopharmacol (2008) 0.99
Insufficient depression treatment in outpatient settings. Ger Med Sci (2004) 0.98
Self-reported utilization of mental health services in the adult German population--evidence for unmet needs? Results of the DEGS1-Mental Health Module (DEGS1-MH). Int J Methods Psychiatr Res (2014) 0.96
Schizoaffective Disorder in the DSM-5. Schizophr Res (2013) 0.95
Effects of abstinence on brain morphology in alcoholism: a MRI study. Eur Arch Psychiatry Clin Neurosci (2009) 0.94
Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol (2008) 0.93
The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimer's dementia. Psychiatry Res (2010) 0.93
Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. Eur Arch Psychiatry Clin Neurosci (2014) 0.93
Outcomes of 1014 naturalistically treated inpatients with major depressive episode. Eur Neuropsychopharmacol (2010) 0.93
Patients' expectations of deep brain stimulation, and subjective perceived outcome related to clinical measures in Parkinson's disease: a mixed-method approach. J Neurol Neurosurg Psychiatry (2013) 0.93
The design and methods of the mental health module in the German Health Interview and Examination Survey for Adults (DEGS1-MH). Int J Methods Psychiatr Res (2013) 0.92
Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr Res (2009) 0.92
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. Eur Arch Psychiatry Clin Neurosci (2014) 0.92
Neurophysiological correlates of impaired facial affect recognition in individuals at risk for schizophrenia. Schizophr Bull (2011) 0.91
Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders. Psychopharmacology (Berl) (2006) 0.91
Impaired Trail-Making Test-B performance in patients with acute schizophrenia is related to inefficient sequencing of planning and acting. J Psychiatr Res (2002) 0.91
Novel schizophrenia risk gene TCF4 influences verbal learning and memory functioning in schizophrenia patients. Neuropsychobiology (2011) 0.91
Genomewide scan and fine-mapping linkage studies in four European samples with bipolar affective disorder suggest a new susceptibility locus on chromosome 1p35-p36 and provides further evidence of loci on chromosome 4q31 and 6q24. Am J Hum Genet (2005) 0.90
Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response? Eur Neuropsychopharmacol (2011) 0.89
Clinical predictors of response and remission in inpatients with depressive syndromes. J Affect Disord (2011) 0.89
αCaMKII autophosphorylation controls the establishment of alcohol drinking behavior. Neuropsychopharmacology (2013) 0.89
Neuropsychological impairments predict the clinical course in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2008) 0.88
Attitude towards adherence in patients with schizophrenia at discharge. J Psychiatr Res (2009) 0.87
Prevention of rehospitalization in schizophrenia: results of an integrated care project in Germany. Eur Arch Psychiatry Clin Neurosci (2009) 0.87
Improving quality of care for depression: the German Action Programme for the implementation of evidence-based guidelines. Int J Qual Health Care (2005) 0.87
Identification of somatic and anxiety symptoms which contribute to the detection of depression in primary health care. Eur Psychiatry (2004) 0.86
Status of psychotic disorders in ICD-11. Schizophr Bull (2012) 0.86
A promoter variant of SHANK1 affects auditory working memory in schizophrenia patients and in subjects clinically at risk for psychosis. Eur Arch Psychiatry Clin Neurosci (2011) 0.85
Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study. J Clin Psychopharmacol (2010) 0.85
Implementation of a schizophrenia practice guideline: clinical results. J Clin Psychiatry (2008) 0.85
Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials. J Clin Psychiatry (2010) 0.85
The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. Int J Neuropsychopharmacol (2008) 0.85
[Cost of care for depressive disorders in primary and specialized care in Germany]. Psychiatr Prax (2004) 0.85
Transient Manic-like Episode Following Bilateral Deep Brain Stimulation of the Nucleus Accumbens and the Internal Capsule in a Patient With Tourette Syndrome. Neuromodulation (2008) 0.85
Clomipramine-induced serum prolactin as a marker for serotonin and dopamine turnover: results of an open label study. Eur Arch Psychiatry Clin Neurosci (2011) 0.84
Disturbed frontal gyrification within families affected with schizophrenia. J Psychiatr Res (2006) 0.84
A coding variant of the novel serotonin receptor subunit 5-HT3E influences sustained attention in schizophrenia patients. Eur Neuropsychopharmacol (2010) 0.84
Internal capsule size associated with outcome in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci (2009) 0.84
DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis. Eur Arch Psychiatry Clin Neurosci (2009) 0.84
Disappearance of self-aggressive behavior in a brain-injured patient after deep brain stimulation of the hypothalamus: technical case report. Neurosurgery (2008) 0.84
Atypical symptoms in hospitalised patients with major depressive episode: frequency, clinical characteristics, and internal validity. J Affect Disord (2007) 0.83
Late-stage neurosyphilis presenting with severe neuropsychiatric deficits: diagnosis, therapy, and course of three patients. J Neurol (2011) 0.83
Influence of synaptic serotonin level on [18F]altanserin binding to 5HT2 receptors in man. Behav Brain Res (2003) 0.83
Needs-oriented discharge planning and monitoring for high utilisers of psychiatric services (NODPAM): design and methods. BMC Health Serv Res (2008) 0.83
The hippocampus in families with schizophrenia in relation to obstetric complications. Schizophr Res (2008) 0.83
Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response. Psychiatry Res (2008) 0.83
Evaluating depressive symptoms in schizophrenia: a psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Psychopathology (2012) 0.83
Response trajectories in "real-world" naturalistically treated schizophrenia patients. Schizophr Res (2012) 0.82
Akathisia and suicidal ideation in first-episode schizophrenia. J Clin Psychopharmacol (2012) 0.82
The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats. Clinics (Sao Paulo) (2010) 0.82
Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenet Genomics (2009) 0.82
Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics (2009) 0.82
Adherence to guidelines for treatment of depression in in-patients. Br J Psychiatry (2005) 0.82
An early improvement threshold to predict response and remission in first-episode schizophrenia. Br J Psychiatry (2010) 0.82
No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. Eur Arch Psychiatry Clin Neurosci (2012) 0.82
The German Research Network on Schizophrenia--impact on the management of schizophrenia. Dialogues Clin Neurosci (2006) 0.81
Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder. J Psychiatr Res (2011) 0.81
Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission? World J Biol Psychiatry (2010) 0.81
Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci (2007) 0.80
Facial expression in male and female schizophrenia patients. Eur Arch Psychiatry Clin Neurosci (2009) 0.80
Prediction of symptom remission in schizophrenia during inpatient treatment. World J Biol Psychiatry (2009) 0.80
One-year functional outcomes of naturalistically treated patients with schizophrenia. Psychiatry Res (2012) 0.80